PDF(Sci-hub)
Abstract：
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer\'s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
摘要：
自WFSBP关于神经退行性痴呆生物标志物的第一份共识论文发表以来的12年中，在该领域取得了巨大的进步，工作队现在有机会扩展和更新原始文件。开发了阿尔茨海默病（AD）的新概念以及AD与AD引起的痴呆之间的概念相互作用。导致两套诊断/研究标准。分析前样品处理程序，生物缓冲,对结果的分析和分析后解释进行了深入研究和优化。引入了一个全球质量控制项目，以评估和监视测量中的中心间差异，以协调结果。使用的背景以及如何在脑脊液（CSF）以外的生物标本中接近候选生物标志物，例如血,被精确定义。神经成像技术取得了重要进展，包括将淀粉样蛋白-β正电子发射断层扫描结果与基于流体的模式进行比较的研究。同样，研究实验室技术的发展，例如超敏感方法，我们希望进一步提高经典和新型候选生物标志物的分析和诊断准确性。协同，在抗痴呆治疗的临床试验的进步激励和激励的努力，以寻找和优化最可靠的早期诊断模式。最后,首次发表的研究探讨了基于生物标志物诊断神经退行性疾病的潜在成本效益.
